IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
Rare Kidney Diseases
IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
Updates in IgA Nephropathy
Learn the latest advancements in the understanding and management of IgA Nephropathy (IgAN) with two expert-led videos sponsored by Otsuka with Professors Brad Rovin, MD (United States) and Jürgen Floege,… Read More
IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
Utilization Of The International IgA Nephropathy Prediction Tool
Learn about the clinical, laboratory and histological risk predictors that make up the International IgAN Prediction Tool and gain an understanding of its clinical utility and future potential. Read More
The Four-Hit Hypothesis & The Role Of APRIL In IgA Nephropathy
The goal of this webinar is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis. Read More